Advertisement
IBO vs LPCN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBO is a Buy and LPCN is a Hold.
IBO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IBO turned positive on October 23, 2026. Looking at past instances where IBO's MACD turned positive, the stock continued to rise in 13 of 15 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBO's RSI Oscillator exited the oversold zone, 5 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 56%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on IBO as a result. In 33 of 41 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +12.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 72 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
IBO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IBO entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IBO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.254) is normal, around the industry mean (3.498). P/E Ratio (0.369) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
LPCN in +12.42% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LPCN advanced for three days, in 209 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LPCN's RSI Indicator exited the oversold zone, 29 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on LPCN as a result. In 66 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for LPCN just turned positive on November 02, 2026. Looking at past instances where LPCN's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
LPCN moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LPCN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
LPCN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LPCN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.595) is normal, around the industry mean (3.498). P/E Ratio (-0.849) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.302) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. LPCN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LPCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IBO | LPCN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 8 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | 75 | |
P/E GROWTH RATING 1..100 | 78 | 16 | |
SEASONALITY SCORE 1..100 | 30 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LPCN's Valuation (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for IBO (82) in the null industry. This means that LPCN’s stock grew somewhat faster than IBO’s over the last 12 months.
LPCN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as IBO (100) in the null industry. This means that LPCN’s stock grew similarly to IBO’s over the last 12 months.
IBO's SMR Rating (8) in the null industry is significantly better than the same rating for LPCN (98) in the Pharmaceuticals Other industry. This means that IBO’s stock grew significantly faster than LPCN’s over the last 12 months.
IBO's Price Growth Rating (62) in the null industry is in the same range as LPCN (75) in the Pharmaceuticals Other industry. This means that IBO’s stock grew similarly to LPCN’s over the last 12 months.
LPCN's P/E Growth Rating (16) in the Pharmaceuticals Other industry is somewhat better than the same rating for IBO (78) in the null industry. This means that LPCN’s stock grew somewhat faster than IBO’s over the last 12 months.
| IBO | LPCN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 56% | 1 day ago 74% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 19% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 20% | 1 day ago 86% |
| Advances ODDS (%) | 2 days ago 79% | 3 days ago 82% |
| Declines ODDS (%) | 13 days ago 90% | 20 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IBO’s FA Score shows that 1 FA rating(s) are green while LPCN’s FA Score has 1 green FA rating(s).
- IBO’s FA Score: 1 green, 4 red.
- LPCN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IBO’s TA Score shows that 4 TA indicator(s) are bullish while LPCN’s TA Score has 4 bullish TA indicator(s).
- IBO’s TA Score: 4 bullish, 4 bearish.
- LPCN’s TA Score: 4 bullish, 5 bearish.
Price Growth
IBO (@Biotechnology) experienced а +14.93% price change this week, while LPCN (@Biotechnology) price change was +8.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
LPCN is expected to report earnings on Mar 11, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IBO and
Correlation & Price change
A.I.dvisor tells us that IBO and PCSA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IBO and PCSA's prices will move in lockstep.
| Ticker / NAME | Correlation To IBO | 1D Price Change % | ||
|---|---|---|---|---|
| IBO | 100% | -6.93% | ||
| PCSA - IBO | 32% Poorly correlated | N/A | ||
| INDP - IBO | 27% Poorly correlated | +10.69% | ||
| LPCN - IBO | 27% Poorly correlated | N/A | ||
| IVVD - IBO | 24% Poorly correlated | +4.33% | ||
| LIMN - IBO | 24% Poorly correlated | +6.14% | ||
More | ||||
LPCN and
Correlation & Price change
A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.
| Ticker / NAME | Correlation To LPCN | 1D Price Change % | ||
|---|---|---|---|---|
| LPCN | 100% | N/A | ||
| SPRY - LPCN | 63% Loosely correlated | +10.64% | ||
| HYFT - LPCN | 43% Loosely correlated | N/A | ||
| ELAB - LPCN | 42% Loosely correlated | -6.51% | ||
| ZNTL - LPCN | 36% Loosely correlated | +5.00% | ||
| GLSI - LPCN | 32% Poorly correlated | +0.12% | ||
More | ||||